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Clinical Practice Guideline for the Management of
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guideline. The aim is to assist clinicians caring for
individuals with glomerulonephritis (GN), both adults and
children. The scope includes various glomerular diseases,
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Kidney International (2021) 100, 753–779nephropathy, nephrotic syndrome, minimal change disease
(MCD), focal segmental glomerulosclerosis (FSGS),
infection-related GN, antineutrophil cytoplasmic antibody
(ANCA) vasculitis, lupus nephritis, and anti–glomerular
basement membrane antibody GN. In addition, this
guideline will be the first to address the subtype of
complement-mediated diseases. Each chapter follows the
same format providing guidance related to diagnosis,
prognosis, treatment, and special situations. The goal of
the guideline is to generate a useful resource for clinicians
and patients by providing actionable recommendations
based on evidence syntheses, with useful infographics
incorporating views from experts in the field. Another aim
is to propose research recommendations for areas where753
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global audience of clinicians treating GN while being
mindful of implications for policy and cost. Development of
this guideline update followed an explicit process whereby
treatment approaches and guideline recommendations are
based on systematic reviews of relevant studies, and
appraisal of the quality of the evidence and the strength of
recommendations followed the “Grading of
Recommendations Assessment, Development and
Evaluation” (GRADE) approach. Limitations of the evidence
are discussed, with areas of future research also presented.
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W e are pleased to present the second edition of KidneyDisease: Improving Global Outcomes (KDIGO)Guideline for the Management of Glomerular Dis-
eases to the providers who care for patients with glomerular
diseases and the patients and families who live with glomer-
ular diseases. This guideline is the culmination of a dedicated
process that began in 2017, at which time a Controversies
Conference was convened to identify important updates and
ongoing needs in the field of glomerular diseases and resulted
in 2 summary documents (Part 1: https://kdigo.org/wp-
content/uploads/2017/02/KDIGO-GN-Conference-Report-
Part-1.pdf; Part 2: https://kdigo.org/wp-content/uploads/2
017/02/KDIGO-GN-Conference-Report-Part-2.pdf). Based
on these conference conclusions, an extensive review of
available literature on glomerular diseases was undertaken by
the Cochrane Kidney and Transplant Evidence Review Team.
This enabled a Work Group of experts in glomerular diseases
to craft a data-driven series of recommendations, and practice
points to facilitate the care and treatment of patients with
glomerular diseases. This guideline supplants the KDIGO
2012 Guideline for Glomerulonephritis (GN). In addition
to this guideline, there are other groups examining trial de-
signs for glomerular diseases and how best to incorporate pa-
tient preferences and outcomes of relevance to patients and
families in trials. Such efforts, like Standardized Outcomes
in Nephrology-Glomerular Diseases (SONG-GD) should be
used in conjunction with the KDIGO guideline.
The guideline is organized into 11 chapters, 10 of which
cover a specific primary or secondary glomerular disease or
group of diseases. The first chapter is an extensive review of
general management principles that should be considered for
patients with any type of glomerular disease. The chapters
provide recommendations that are evidence-based and754actionable. The recommendations are graded to provide the
reader with an idea of the strength of a given recommendation
and quality of the evidence underpinning it. In the many in-
stances where high-confidence data, for example from ran-
domized, controlled clinical trials (RCTs), are lacking, practice
points informed by observational studies, cohort studies, un-
controlled or open-label studies, and expert consensus have been
provided. Practice points should be considered as suggestions to
assist clinicians in managing patients when there is a lack of or
gaps in high-quality evidence for a given topic or issue.
This Executive Summary provides highlights of the
KDIGO 2021 guideline and in general, summarizes what is
the same, what is new, and what remains in need of more
evidence in comparison to the 2012 guideline. The summary
is organized into chapter discussions that follow the outline
of the guideline. Given the extensive scope of this guideline,
this summary is not comprehensive and the reader is
referred to the full guideline for details and discussion of the
flow of evidence and logic leading to the recommendations
and practice points (https://kdigo.org/guidelines/gd/). We
have not included references in the Executive Summary as
the guideline itself is extensively referenced. The evidence
used to generate the guideline is available in the Data Sup-
plement published alongside the guideline and will be
published on the MAGICapp platform (https://kdigo.org/
guidelines/gd/).
Chapter 1: General principles for the management of
glomerular disease
This chapter emphasizes the role of the kidney biopsy, which is
still considered the “gold standard” for the diagnostic evalua-
tion of glomerular diseases. Repeat kidney biopsy should be
performed if the information will potentially alter the diag-
nosis, the therapeutic plan, or contribute to the estimation of
prognosis. Serologic studies and genetic testing (e.g., whole
exome sequencing) in selected cases may enhance the inter-
pretation and the utility of the kidney biopsy in the future.
To assess total urinary protein excretion in patients with
GN, a 24-hour urine collection should be obtained. In
children, a first morning protein-creatinine ratio (PCR) is
more appropriate. When feasible, a reasonable compromise
is to collect an “intended” 24-hour urine sample and
measure PCR in an aliquot of the collection. To assess
estimated glomerular filtration rate (eGFR), the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
creatinine equation is preferred in adult patients with GN
and the modified Schwartz equation in children. The Full
Age Spectrum (FAS) equation may be used in both adults
and children. Issues of race in these formulae are now being
clarified by the National Kidney Foundation-American
Society of Nephrology Task Force. Routine evaluation of
urine sediment for erythrocyte morphology and the pres-
ence of red cell casts and/or acanthocytes is indicated in all
forms of GN.
Edema management in nephrotic syndrome (NS) has not
changed significantly from the 2012 guideline version. LoopKidney International (2021) 100, 753–779
Figure 1 | Minimization of immunosuppression-related adverse effects. GFR, glomerular filtration rate.
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sodium intake. If diuretic response is insufficient, other
mechanistically different diuretics should be added. In such
cases, particular attention to adverse effects of the diuretics is
necessary, including hyponatremia, hypokalemia, glomerular
filtration rate (GFR) reduction, and volume depletion.
Management of hypertension and proteinuria in GN also
has experienced few changes. Angiotensin-converting
enzyme inhibitors (ACEi) or angiotensin II receptor
blockers (ARBs) should be used at maximally tolerated or
allowed dose as first-line in treating patients with both hy-
pertension and proteinuria. Target systolic blood pressure in
most adult patients is <120 mm Hg using standardized of-
fice BP measurement (https://kdigo.org/guidelines/blood-
pressure-in-ckd/). Target 24-hour mean arterial pressure in
children is #50th percentile for age, sex, and height by
ambulatory blood pressure monitoring. Clinicians should
up-titrate an ACEi or ARB to maximally tolerated or allowed
daily dose as first-line in treating patients with GN and
proteinuria alone and advise on sodium restriction, but
counsel patients to hold renin-angiotensin system (RAS)
inhibitors and diuretics if they are at risk for volume
depletion such as an intercurrent illness. Proteinuria goal isKidney International (2021) 100, 753–779variable depending on the GN-type (see individual chap-
ters). If needed, potassium-wasting diuretics and/or
potassium-binding agents can be used to reduce serum
potassium to normal, in order to allow the use of RAS in-
hibitors for blood pressure control and proteinuria reduc-
tion. Metabolic acidosis should be treated if serum
bicarbonate is <22 mmol/l. Lifestyle modifications should
be employed in all GN patients as synergistic means for
improving control of hypertension and proteinuria.
Treatment of dyslipidemia may be considered in patients
with the NS, particularly for patients with other cardiovas-
cular risk factors, including hypertension and diabetes. Life-
style modifications are important in all patients with
persistent dyslipidemia and glomerular disease. Consider
starting a statin drug as first-line therapy for persistent dys-
lipidemia in patients with glomerular disease and consider
initiation of non-statin therapy in those individuals who
cannot tolerate a statin, or who are at high atherosclerotic
cardiovascular disease risk and fail to achieve low-density li-
poprotein cholesterol or triglyceride goals despite maximally
tolerated statin dose.
Full anticoagulation is indicated for patients with
thromboembolic events occurring in the context of NS.755
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tients with NS when the risk of thromboembolism exceeds
the estimated patient-specific risks of an anticoagulation-
induced serious bleeding event. A particular high-risk
situation is membranous nephropathy (MN) with NS; a
decision algorithm in this situation is shown in the section
related to Chapter 3 (see below).
To prevent infections in GN patients with impaired im-
munity, pneumococcal vaccine should be administered to
those with NS and/or chronic kidney disease (CKD). Patients
and household contacts should receive the influenza vaccine.
Screening for tuberculosis (TB), hepatitis B virus (HBV),
hepatitis C virus (HCV), human immunodeficiency virus
(HIV), and syphilis in clinically appropriate patients is sug-
gested. Prophylactic trimethoprim-sulfamethoxazole should
be considered in patients receiving high-dose prednisone or
other immunosuppressive agents (rituximab, cyclophospha-
mide). Meningococcal vaccine and prophylaxis are necessary
in patients with complement deficiencies or treated with
complement inhibitors.
Outcome measures, such as treatment goals for protein-
uria reduction, vary between the specific causes of GN. A
reduction in the slope of decline in GFR can be taken as a
favorable surrogate outcome of treatment. A 40% or greater
decline in eGFR from baseline over a 2- to 3-year period has
been suggested as a surrogate outcome measure for kidney
failure in clinical trials.
Figure 1 shows options for minimization of
immunosuppression-related adverse effects.
Dietary modifications and regular physical activity to
normalize body mass index, limit central obesity, and
decrease cardiovascular disease risk factors are appropriate.
Patients should be counseled to restrict dietary sodium
to <2.0 g/d (<90 mmol/d). Dietary protein restriction may
be considered in adults based on the degree of proteinuria
and level of kidney function, with replacement of nephrotic
losses.
Care for pregnant patients with GN needs coordination
between nephrology and obstetrics, and ideally, planning for
pregnancy should be considered.
Patients with GN should be offered participation in a
disease registry and clinical trials, whenever available.
Chapter 2: Immunoglobulin A nephropathy (IgAN)/
immunoglobulin A vasculitis (IgAV)
Following the biopsy-confirmed diagnosis of IgAN, including
histologic scoring via the MEST-C (mesangial [M] and
endocapillary [E] hypercellularity, segmental glomerulo-
sclerosis [S], interstitial fibrosis/tubular atrophy [T], and
crescents [C]) system, it is essential to assess disease prog-
nosis. A valuable resource is the International IgAN Predic-
tion Tool available at Calculate by QxMD. It is important to
realize however that neither this calculator nor the MEST-C
score nor the presence or number of crescents can presently756be used to determine the likely impact of any particular
treatment regimen.
As in the 2012 guideline version, the primary focus of
IgAN management should be multifaceted, optimized
supportive care, including RAS blockade as much as tolerated
or allowed, blood pressure control, cardiovascular risk
minimization, adherence to lifestyle advice, including dietary
counselling, smoking cessation, weight control, and exercise
as appropriate. RAS blockade should be instituted irrespective
of hypertension if the patient has proteinuria >0.5 g/d
(Grade 1B).
If proteinuria stays above 0.75–1 g/d despite at least 90
days of optimized supportive care, the patient has a high
risk of progressive loss of kidney function and may be
considered for a 6-month course of glucocorticoid therapy
(Grade 2B), or preferably, the opportunity to take part in a
therapeutic clinical trial. Because the clinical benefit of
glucocorticoids in IgAN is not established, they should be
given with extreme caution or avoided entirely in patients
with:
 an eGFR <30 ml/min per 1.73 m2,
 diabetes,
 obesity (defined as body mass index >30 kg/m2),
 latent infections (e.g., viral hepatitis, tuberculosis),
 secondary disease (e.g., liver cirrhosis),
 active peptic ulceration,
 uncontrolled psychiatric disease, or
 severe osteoporosis.
Management of the patient with IgAN who remains at
high risk for progression after maximal supportive care is
illustrated in Figure 2. Proteinuria reduction to under 1 g/d is
a surrogate marker of improved kidney outcome in IgAN, and
hence a reasonable treatment target.
Beyond glucocorticoids, other immunosuppressive thera-
pies are not recommended in IgAN, including azathioprine,
cyclophosphamide (except in the setting of rapidly
progressive IgAN), calcineurin inhibitors (CNIs), and ritux-
imab. The use of mycophenolate mofetil (MMF) in IgAN is
not recommended in non-Chinese patients, whereas it may be
used as a glucocorticoid-sparing agent in Chinese patients.
Similarly, in non-Japanese patients there are no data to sup-
port the routine use of tonsillectomy in high risk IgAN pa-
tients. If immunosuppression is being considered, a detailed
discussion of the risks and benefits of each drug should be
undertaken with the patient, recognizing that adverse treat-
ment effects are more likely in patients with an eGFR <50 ml/
min per 1.73 m2.
A number of new therapies for high-risk IgAN patients are
currently being evaluated, including drugs that may augment
the supportive care approach (sodium-glucose co-
transporter-2 [SGLT2] inhibitors, sparsentan, atrasentan,
hydroxychloroquine) or more specific approaches (e.g.,
enteric-coated budesonide, various complement inhibitors,
therapies targeting B-cell development).Kidney International (2021) 100, 753–779
Figure 2 | Management of patients with IgAN who remain at high risk for progression after maximal supportive care. *IgAN with
rapidly progressive glomerulonephritis is covered in Practice Point 2.4.3. †The Therapeutic Evaluation of Steroids in IgA Nephropathy Global
(TESTING) study shows early evidence of efficacy in patients who had marked proteinuria (2.4 g/d average) at the expense of treatment-
associated morbidity and mortality. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure;
eGFR, estimated glomerular filtration rate; GN, glomerulonephritis; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency
virus; IgAN, immunoglobulin A nephropathy; TB, tuberculosis.
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Patients with a kidney biopsy demonstrating mesangial IgA
deposition and histologic features consistent otherwise with
minimal change disease (MCD) should be treated in accor-
dance with the guidelines for MCD (Chapter 5). Patients with
NS whose kidney biopsy has coexistent features of a mesan-
gioproliferative GN should be managed in the same way as
high-risk IgAN patients. Finally, nephrotic range proteinuria
without NS may be seen in IgAN, and this commonly reflects
coexistent secondary focal segmental glomerulosclerosis
(FSGS) (e.g., obesity, uncontrolled hypertension) or devel-
opment of extensive glomerulosclerosis and tubulointerstitial
fibrosis.
IgAN can also lead to acute kidney injury (AKI) from
severe visible hematuria, in which case management should
focus on supportive care for AKI. A repeat kidney biopsy
should be considered in patients who fail to show improve-
ment in kidney function within 2 weeks following cessation of
the hematuria. Alternatively, AKI can result from a rapidlyKidney International (2021) 100, 753–779progressive glomerulonephritis (RPGN) IgAN course with
extensive crescent formation (usually >50% of glomeruli),
commonly in the absence of visible hematuria. Importantly,
the presence of crescents in a kidney biopsy in the absence of
a concomitant change in GFR does not constitute rapidly
progressive IgAN; however, these patients require close
follow-up to ensure prompt detection of any GFR decline.
Patients with true rapidly progressive IgAN should be
offered treatment with cyclophosphamide and glucocorti-
coids in accordance with the guidelines for antineutrophil
cytoplasmic antibody (ANCA)–associated vasculitis (AAV;
Chapter 9).
There are insufficient data currently to recommend that
post-pubertal children be managed as adults with IgAN.
There is strong evidence suggesting a benefit of RAS blockade
in children. In children the use of immunosuppressants is
more widespread, particularly the early use of glucocorticoids,
but trial-based evidence that may inform recommendations is
absent.757
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upon criteria for the diagnosis of IgAV in adults,
although a clinical diagnosis of IgAV is often made in adults
based on the criteria described for children. Adult patients
with IgAV should be assessed for secondary causes and for
malignancy with age- and sex-appropriate screening tests.
Neither the MEST-C classification nor the International
IgAN Prediction Tool has been validated in IgAV. Sup-
portive care measures do not differ from those in patients
with IgAN.
Glucocorticoids should not be used to prevent nephritis in
patients with isolated extrarenal IgAV (Grade 1B). In those
patients who wish to try immunosuppressive therapy, treat-
ment with glucocorticoids is as described above for IgAN.
IgAV nephropathy (IgAVN) with RPGN may also be associ-
ated with significant extrarenal involvement (e.g., pulmonary,
gastrointestinal, and skin), which may dictate alternative
immunosuppressive strategies. Uncontrolled case series
describe the potential role for the addition of plasma ex-
change to glucocorticoid therapy to accelerate recovery in
patients with life- or organ-threatening extrarenalFigure 3 | Clinical criteria for assessing risk of progressive loss of kidn
biomarkers may not be available in all centers; this table provides an
creatine (SCr) values to guide management, and SCr values >1.5 mg
eGFR value of 60 ml/min per 1.73 m2 defines kidney insufficiency in
age, and an SCr value of 1.5 mg/dl (133 mmol/l) reflects an eGFR of 50
per 1.73 m2 in a 60-year-old female patient. Thus, when using eGFR
albumin should be measured by BCP or immunometric assay. ‡Cuto
measured at 3–6-month intervals, the shorter interval being perform
Changes in anti-PLA2R antibodies levels during follow-up likely add
precedes clinical remission and should lead to refraining from addit
calculated as clearance of IgG/clearance of albumin. ACEi, angiotens
blocker; BCP, bromocresol purple; eGFR, estimated glomerular filtrati
M-type phospholipase A2 receptor.
758complications of IgAV. The majority of IgAV children who
will develop nephritis will do so within 3 months of pre-
sentation. Oral prednisone/prednisolone or pulsed intrave-
nous methylprednisolone should be used in children with
mild or moderate IgAVN. Children with IgAVN and NS and/
or rapidly deteriorating kidney function are treated in the
same way as rapidly progressive IgAN.
Chapter 3: Membranous nephropathy
In contrast to the KDIGO 2012 guidelines, a kidney biopsy is
no longer required to confirm the diagnosis of MN in patients
with NS and a positive anti-M-type phospholipase A2 receptor
(PLA2R) antibody test. Nevertheless, a kidney biopsy can
provide important additional information even under these
circumstances. Patients with MN should be evaluated for
associated conditions (e.g., malignancy, infections, lupus,
drugs), regardless of whether anti-PLA2R antibodies and/or
anti–thrombospondin type-1 domain-containing 7A
(THSD7A) or other antibodies are present or absent. Clinical
and laboratory criteria should then be used to assess the risk of
progressive loss of kidney function (Figure 3).ey function. eGFR and PCR are used in routine clinical care. Other
overview of useful biomarkers. *Most studies have used serum
/dl (133 mmol/l) are often used to define kidney insufficiency. An
a young adult. It is important to realize that eGFR decreases with
ml/min per 1.73 m2 in a 60-year-old male patient and 37 ml/min
in risk estimation, age should be taken into account. †Serum
ff values are not validated. Anti-PLA2R antibodies should be
ed in patients with high anti-PLA2R antibodies levels at baseline.
to risk estimation. Disappearance of anti-PLA2R antibodies
ional therapy. Detailed data are lacking. §Selectivity index is
in-converting enzyme inhibitor; ARB, angiotensin II receptor
on rate; IgG, immunoglobulin G; PLA2Rab, antibodies against the
Kidney International (2021) 100, 753–779
Figure 4 | Risk-based treatment of MN. *See Practice Point 3.2.1 and Figure 3 for a detailed description of risk evaluation. †Calcineurin
inhibitor (CNI) monotherapy is considered less efficient. Treatment with CNI for 6–12 months with rapid withdrawal is associated with a high
relapse rate. Still, its use may be considered in patients with normal eGFR and moderate risk of progression, since many of these patients will
develop a spontaneous remission. The use of CNI will shorten the period of proteinuria. In patients with high risk of progression, addition of
rituximab after 6 months of treatment with CNI is advised, with the possible exception of patients with documented disappearance of anti-
PLA2R antibodies after CNI treatment. ‡There is insufficient evidence that rituximab used in standard doses prevents development of kidney
failure. If eGFR falls below 50 ml/min per 1.73 m2, the doses of cyclophosphamide should be halved. In patients who do not tolerate or can no
longer use cyclophosphamide, rituximab could be offered. Consultation with an expert center is advised. eGFR, estimated glomerular filtration
rate; MN, membranous nephropathy; PLA2R, M-type phospholipase A2 receptor.
Figure 5 | Immunologic monitoring in MN after start of therapy. See text for current treatment schedules. Note: The cumulative dose of
cyclophosphamide should not exceed 36 g in view of the risk of malignancy (Chapter 1). To stay on the safe side, we usually limit the cumulative
dose to 25 g (in an 80 kgmale: 6months cyclical cyclophosphamide at a dose of 2.5mg/kg/d equals 18 g and 6months daily cyclophosphamide at
a dose of 1.5 mg/kg/d equals 22 g). Lower doses (maximum 10 g) must be used in patients who wish to conceive. CNIs are unlikely to induce late
immunologic remission; in patients with persistent anti-PLA2R antibodies, these drugs may be used in combination with rituximab. B cell
depletion is insufficient to judge the efficacy of rituximab therapy; extra dosesmay be considered even if B cells in the peripheral blood are absent
or very low. However, in these patients, consultation with an expert center is advised. eGFR should be stable; if not, then it is always necessary to
evaluate for other causes; and if eGFR decrease is attributed to MN activity, always provide additional therapy. *Some centers will measure anti-
PLA2R antibodies at month 3, and adapt treatment at that time. In most patients, response occurs within 3 months after start of therapy. †A
negative immunofluorescence test indicates immunologic remission. Ifmeasured by enzyme-linked immunosorbent assay, a cutoff value of 2 RU/
ml should be used to define complete immunologic remission. ‡Retreatment with rituximab should be given similarly to the initial treatment with
1 or 2 infusions of 1 g rituximab each administered 2 weeks apart (Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the
treatment of membranous nephropathy. N Engl J Med. 2019;381:36–46). CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; MN,
membranous nephropathy; PLA2Rab, antibodies against the M-type phospholipase A2 receptor.
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Figure 6 | Management of resistant disease in MN. Details of commonly used treatment regimens are shown in Figure 32 of the full
guideline text. *Evaluation: In patients with resistant disease, compliance should be checked and efficacy monitored (e.g., B-cell response, anti-
rituximab antibodies, IgG levels, leukocytopenia during cyclophosphamide, CNI levels). Persistent proteinuria is not sufficient to define
resistance. If proteinuria persists, while serum albumin has increased, one should also consider secondary FSGS. This would be further
supported by the disappearance of anti-PLA2R antibodies. In patients with persistent proteinuria with normal or near-normal serum albumin
levels or patients with persistent proteinuria despite loss of anti-PLA2R antibodies, a kidney biopsy should be considered to document active
MN. †Second treatment is dependent on the severity of deterioration of eGFR as indicated. When rituximab is chosen as second treatment, the
response of proteinuria and anti-PLA2R antibodies should be evaluated after 3 months. Cyclophosphamide treatment should take into account
the maximal tolerable dose: The cumulative dose should not exceed 10 g if preservation of fertility is required. The cumulative dose should not
exceed 36 g to limit risk of malignancies. Expert centers may still use more, based on weighing risk and benefits. ‡Patients who did not respond
to rituximab or cyclophosphamide should have a consultation with an expert center. These centers may choose experimental therapies
(bortezomib, anti-CD38 therapy, and belimumab) or a higher dose of conventional immunosuppressive therapy. CNI, calcineurin inhibitor;
eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; MN, membranous nephropathy; PLA2R, M-type
phospholipase A2 receptor.
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receive optimal supportive care. Immunosuppressive ther-
apy is not required in patients with proteinuria <3.5 g/d,
serum albumin >30 g/l by bromocresol purple (BCP) or
immunometric assay, and eGFR >60 ml/min per 1.73 m2.
Immunosuppressive therapy should be considered when at
least one risk factor for disease progression is present or
when serious complications of NS (e.g., AKI, infections,
thromboembolic events) have occurred (Figure 4). For pa-
tients with MN and at least one risk factor for disease
progression, consider using rituximab or cyclophosphamide
and alternate month glucocorticoids for 6 months, or
tacrolimus-based therapy for $6 months, depending on the
estimate of risk (Figures 3 and 4) (Grade 1B). Longitudinal
monitoring of anti-PLA2R antibody levels after starting
therapy may be useful for evaluating treatment response in
patients with MN, and can be used to guide adjustments to
therapy (Figure 5).
In patients with MN and initial relapse of the NS after
therapy, the initial therapy can be repeated or treatment
may be switched to rituximab in those initially treated with760CNIs or cyclophosphamide. Management suggestions for
the patient with treatment-resistant MN are shown in
Figure 6.
Evaluation of a kidney transplant recipient with
MN should include maximal efforts to ascertain if
MN is associated with PLA2R antibodies, including
staining the native kidney biopsy for PLA2R expres-
sion in immune deposits (enhanced PLA2R staining).
The risk of recurrence increases if PLA2R antibodies
persist in the circulation despite kidney failure. After
transplantation, patients with known PLA2R antibody-
associated MN should be monitored for the kinetics
of antibody levels every 1–3 months with a liberal
transplant biopsy in case of increasing antibodies.
Rituximab can be used in case of documented
recurrent MN.
MN in children is very rare and no evidence to guide
management exists. Such children should be referred to an
expert center.
Prophylactic anticoagulant therapy in patients with MN
and NS should be based on an estimate of the risk ofKidney International (2021) 100, 753–779
Figure 7 | Anticoagulant therapy in patients with MN. Adapted from Kidney International, volume 89, issue 5, Hofstra JM, Wetzels JFM.
Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy? Pages 981–983,
Copyright ª 2016, with permission from the International Society of Nephrology. Proposed algorithm for anticoagulant therapy in
patients with membranous nephropathy (MN). This algorithm provides guidance for the clinicians. The proposed cutoff values are based
on expert opinion. When considering anticoagulant therapy, it is important to balance benefits and risks. The following are important
considerations:
1. The risk of thrombotic events is related to the level of serum albumin. It is important to note that there is a large difference among the serum
albumin assays. A serum albumin concentration of 25 g/l [2.5 g/dl] with bromocresol green (BCG) equals a concentration ofw20 g/l [2.0 g/dl]
with bromocresol purple (BCP), or immunonephelometry. It is likely that most studies have used the BCG assay. Consider using 25 g/l [2.5 g/
dl] as a threshold when using BCG and 20 g/l [2.0 g/dl] when using BCP or immunonephelometry.
2. Assess risk of venous thrombosis and risk of bleeding (http://www.med.unc.edu/gntools/).
3. Patients with MN and nephrotic syndrome are also at risk of developing arterial thrombotic events. The risk of arterial thrombotic
event (ATE) is dependent on age, history of previous events, diabetes, estimated glomerular filtration rate (eGFR), smoking, and
severity of nephrotic syndrome (NS). Risk assessment can be done using the Framingham risk score, and including previous events
and proteinuria.
4. Use of aspirin is insufficient to prevent venous thromboembolism (VTE); use of warfarin is sufficient to prevent ATE.
5. Treatment with warfarin: There is more international normalized ratio (INR) variability in patients with NS and low eGFR; there is increased
risk of thrombosis immediately after starting high-dose warfarin. Consider starting anticoagulation therapy with low-dose low-molecular-
weight heparin and then folding in warfarin and, when therapeutic, stopping the heparin. A good alternative is to use low-dose low-
molecular-weight heparin þ aspirin for a period of 3 months before switching to warfarin, allowing for judgment on the course of
proteinuria.
6. Glucocorticoids increase the risk of thrombosis; thus, anticoagulant therapy should not be omitted in patients who start prednisone
therapy.
7. ATE risk is estimated using the Framingham risk score, with added risk in case of low eGFR or higher proteinuria. The Framingham risk score
takes into account age, smoking, serum cholesterol, and blood pressure.
BH Rovin et al.: Executive summary of KDIGO 2021 glomerular diseases KD IGO execu t i ve conc lu s i onsthrombotic events and the risk of bleeding complications, as
illustrated in Figure 7.
Chapter 4: Nephrotic syndrome in children
In contrast to the management of NS in adults, a diagnostic
kidney biopsy is generally not performed at presentation in
children to establish a diagnosis. Children who develop NS
are generally assumed to have MCD that will respond to
glucocorticoids (steroid-sensitive nephrotic syndrome
[SSNS]). Patients who are glucocorticoid-resistant (steroid-
resistant nephrotic syndrome [SRNS]) have poor long-term
kidney survival, and should undergo a more extensive eval-
uation, including a kidney biopsy and genetic testing
(Figure 8).Kidney International (2021) 100, 753–779Since the 2012 guideline, several trials demonstrated that
a shorter initial course of glucocorticoids has comparable
efficacy to a 6-month course, leading to the updated
recommendation that children be treated with high-dose
glucocorticoids for a total of 8–12 weeks instead of 24
weeks (Grade 1B). This will help to decrease treatment
toxicity, especially given that SSNS often relapses and mul-
tiple glucocorticoid courses may be given to an individual.
Building on the theme of lowering glucocorticoid burden,
the Work Group also recommended that children who
frequently relapse or who have become glucocorticoid-
dependent be treated for a week with 0.5 mg/kg/d of
prednisone (or prednisolone) during upper respiratory in-
fections to reduce relapse risk and the need for restarting761
Figure 8 | Treatment algorithm for NS in a newly nephrotic child. Therapeutic approach to NS in children from onset. Refer to clinical trial
where appropriate. *Glucocorticoids: p.o. prednisone or prednisolone. NS, nephrotic syndrome.
KDIGO execu t i ve conc lu s i ons BH Rovin et al.: Executive summary of KDIGO 2021 glomerular diseaseshigh-dose glucocorticoids (Grade 1C). Additionally, for
SSNS patients who frequently relapse and have
glucocorticoid-related side effects, and all glucocorticoid-
dependent patients, consideration should be given to
switching the patients to a glucocorticoid-sparing agent
(Grade 1B). A variety of glucocorticoid-sparing agents have
been used in SSNS (Figure 9). Recent encouraging results
have indicated that a therapeutic agent that is unavailable in
many countries, levamisole, may be an effective, safe, and
inexpensive option, especially in frequently relapsing forms
of NS, and the effectiveness of rituximab in both frequently
relapsing and steroid-dependent forms suggests a pivotal
role of B cells in this disease.762For children with SRNS, CNIs are recommended as the
initial therapy after glucocorticoid failure (Grade 1C).
Cyclophosphamide should be used only if CNIs are not
available in low-resource settings, and the role of rituximab
seems to be limited. For patients who do respond to a CNI,
a switch to MMF to maintain remission should be
considered to avoid long-term CNI toxicity. Importantly,
genetic testing may help clarify the use of immunosup-
pressive agents in SRNS. Although some podocyte muta-
tions may respond to a CNI or other interventions, the vast
majority will not, and knowing this may provide justifi-
cation to reduce the exposure of a child to a potentially
toxic medication.Kidney International (2021) 100, 753–779
Figure 9 | | Glucocorticoid-sparing therapies in children with SSNS. †Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus
cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24:1689–1697. *The CNI, while often used
twice daily, may be dosed once a day, depending on individual formulations. Blood levels of CNI do not provide information on intracellular
levels. The target ranges for CNIs have been based on the transplant literature. The KDIGO Work Group acknowledges that targets for
glomerular diseases are not known. Most clinicians check these levels to verify adherence and avoid CNI toxicity. At present, the most
reasonable dosing of a CNI may be to titrate in the individual patient to obtain the desired effect on proteinuria, balancing dose escalation
against serum creatinine and reducing the dose if serum creatinine increases but does not plateau or increases over 30% of baseline. If the
serum creatinine level does not fall after dose reduction, the CNI should be discontinued. ANCA, antineutrophil cytoplasmic antibody; CBC,
complete blood count; CNI, calcineurin inhibitor; SSNS, steroid-sensitive nephrotic syndrome.
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Figure 10 | Initial treatment of MCD in adults. The optimal glucocorticoid regimen is not well defined; however, suggested doses are
outlined in Figure 45 of the full guideline. The choice of medication should be based on physician and patient preference. MCD, minimal
change disease.
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In contrast to children, MCD in adults requires biopsy
confirmation. Long-term kidney survival is excellent in MCD
patients who respond to glucocorticoids, but less certain for
patients who do not respond. High-dose oral glucocorticoids
constitute initial treatment for MCD (Grade 1C) unless there
are contraindications to glucocorticoids, in which case alter-
natives include cyclophosphamide, CNIs, MMF, and, possibly,
rituximab (Figure 10). The optimal glucocorticoid regimen is
not well-defined; however, high-dose glucocorticoid treat-
ment for MCD should be given for no longer than 16 weeks.
Tapering of glucocorticoids should start 2 weeks after
remission.
Infrequent relapses should be treated with glucocorticoids.
Cyclophosphamide, rituximab, CNIs, or mycophenolic acid
analogs (MPAA) should be employed for the treatment of
frequently relapsing/glucocorticoid-dependent MCD (Grade
1C). An algorithm for treatment of frequently relapsing/
glucocorticoid-dependent MCD in adults is shown in
Figure 11.Figure 11 | Treatment of frequently relapsing/steroid-dependent MC
and patient preference. MCD, minimal change disease.
764Chapter 6: Focal segmental glomerulosclerosis
Advances in the management of glomerular diseases that
demonstrate FSGS lesions on light microscopy have been
confounded by the absence of a rigorous classification of the
diseases that lead to an FSGS pattern of injury, coupled with a
poor understanding of the molecular pathways involved in
disease pathogenesis. To clearly illustrate the heterogeneity of
the processes that can result in FSGS histology, the Work
Group proposed a revised classification of FSGS (Figure 12).
An important suggestion of the proposed classification
system is to eliminate the term idiopathic from the FSGS
lexicon, and to only use primary FSGS for the disease entity
presumably caused by an as of yet unidentified podocyte-toxic
factor that is often amenable to treatment. The new system
adds a category of FSGS of undetermined cause (FSGS-UC).
These patients have an FSGS lesion on kidney biopsy, but do
not have an identifiable underlying cause of FSGS or the
clinicopathologic features of primary FSGS. FSGS-UC patients
bear careful scrutiny as changes in their clinical characteristics
may prompt a second biopsy, supporting a need for treatment.D in adults. The choice of medication should be based on physician
Kidney International (2021) 100, 753–779
Figure 12 | Proposed classification of FSGS. FSGS, focal segmental glomerulosclerosis.
BH Rovin et al.: Executive summary of KDIGO 2021 glomerular diseases KD IGO execu t i ve conc lu s i onsThis revised classification leads to a diagnostic and treat-
ment algorithm designed to focus immunosuppressive thera-
pies only to those patients likely to benefit and avoid their use
in patients not likely to respond (Figure 13). The classification
scheme and treatment algorithm also demonstrate the
important gaps in knowledge and resources that need to be
addressed by the nephrology community for the proper
management of FSGS. For example, without knowing theFigure 13 | Evaluation of a patient with FSGS lesion on the kidney b
Figure 53, please see full guideline. FSGS, focal segmental glomeruloscle
Kidney International (2021) 100, 753–779podocyte-toxic factor(s) that mediates primary FSGS, diag-
nosis of primary FSGS is based on a clinical presentation of
full-blown nephrotic syndrome often of sudden onset, and
diffuse foot process effacement by electron microscopy, a
technology that is not routinely available throughout the
world. The appropriate use of genetic evaluation in adults with
FSGS remains unclear, and even when indicated requires an
often unavailable or costly expertise to interpret the results.iopsy and no evidence of other glomerular pathology. *For
rosis.
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Figure 14 | Treatment protocols for FSGS. *The target ranges for CNIs have been based on the transplant literature. The KDIGO Work Group
acknowledge that targets for glomerular diseases are not known. Most clinicians check these levels to verify adherence and avoid CNI toxicity.
At present, the most reasonable dosing of a CNI may be to titrate in the individual patient to obtain the desired effect on proteinuria, balancing
dose escalation against serum creatinine and reducing the dose if serum creatinine increases but does not plateau or increases over 30% of
baseline. If the serum creatinine level does not fall after dose reduction, the CNI should be discontinued. CNI, calcineurin inhibitor; FSGS, focal
segmental glomerulosclerosis.
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mary FSGS remain the same as the 2012 recommendations.
High-dose glucocorticoids are recommended as first-line
therapy (Grade 1D), and for glucocorticoid-resistant or
intolerant patients, a trial of a CNI is recommended (Grade
1C). The use of oral predniso(lo)ne at a dose of 1 mg/kg/
d has the potential for severe toxicity, so application of this
recommendation requires close supervision for side effects
and a maximum duration of 16 weeks is suggested.
Additionally, patients who are expected to respond to
glucocorticoids usually show at least some improvement in
proteinuria within 4–8 weeks. In the setting of no766indication of response and/or severe glucocorticoid side
effects, it is prudent to move patients to second-line
therapy with a CNI. The overall duration of glucocorti-
coids should be 6 months (high-dose period plus taper),
and the overall duration of CNIs should be 12 months.
Suggested treatment protocols are outlined in Figure 14. If
patients have not responded to glucocorticoids or a CNI,
the therapeutic choices for primary FSGS are limited.
Several other immunosuppressive agents have been tried,
but there are no high-quality data supporting their use
(Figure 14). This speaks to the importance of considering
FSGS patients for clinical trials, and for trying to identifyKidney International (2021) 100, 753–779
BH Rovin et al.: Executive summary of KDIGO 2021 glomerular diseases KD IGO execu t i ve conc lu s i onsthe circulating factor(s) mediating FSGS, as this may lead
to more targeted therapies with less toxicity than long-
term, high-dose glucocorticoids or CNIs.
Chapter 7: Infection-related glomerulonephritis
Bacterial infection-related GN. Kidney biopsy can be
useful in suspected bacterial infection-related GN, partic-
ularly when culture evidence of infection is elusive or the
diagnosis is in doubt, to assess prognosis, and/or for po-
tential therapeutic reasons. In some cases, biopsy may be
critical at arriving at the correct diagnosis, as comorbidities
contribute to difficulty in making the diagnosis
(Figure 15).
Prognosis and therapy of classic bacterial infection-
related GN syndromes depends on the underlyingFigure 15 | Evaluation of classic bacterial infection-related GN syndr
ANCA, antineutrophil cytoplasmic antibody; eGFR, estimated glomerular
glomerulonephritis; HIV, human immunodeficiency virus; PCR, protein-cr
Kidney International (2021) 100, 753–779infection. In general, prognosis is good with early diagnosis
and antibiotic treatment of the infection. However, in IgA-
dominant infection-related GN, dialysis is frequently
required in the acute phase and <20% of the patients re-
turn to their premorbid levels of kidney function. The
utility of immunosuppression, even in cases of crescentic
GN, is uncertain and carries substantial potential risks, in
particular in the elderly. In classical postinfectious GN,
persistently low C3 in serum beyond week 12 may be an
indication for kidney biopsy to particularly exclude com-
plement C3 glomerulonephritis (C3GN).
Hepatitis C infection-related GN. The Work Group concurs
fully with Recommendations 5.1 through 5.2.3 of the KDIGO
2018 Clinical Practice Guideline for the Prevention, Diagnosis,
Evaluation, and Treatment of Hepatitis C in Chronic Kidneyomes. ACR, albumin-creatinine ratio; ANA, antinuclear antibody;
filtration rate; GBM, glomerular basement membrane; GN,
eatinine ratio; PR3, proteinase 3.
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mendations, selection and dosing of specific therapeutic
agents, and research recommendations (https://kdigo.org/wp-
content/uploads/2017/02/KDIGO-2018-Hep-C-GL.pdf).
Hepatitis B infection-related GN. Patients with proteinuric
glomerular disease should undergo testing for HBV infection,
and adult patients with chronic HBV infection should be
considered at risk for the development of kidney failure. We
recommend that patients with replicative HBV infection (as
denoted by HBV DNA levels >2000 IU/ml) and GN receive
treatment with nucleos(t)ide analogues, as recommended for
the general population by standard clinical practice guidelines
for HBV infection (Grade 1C). Immunosuppressive agents,
such as cyclophosphamide or rituximab, may accelerate HBV
replication and should be avoided in patients with untreated
replicative HBV infection and GN.
Rituximab and cyclophosphamide should be avoided in
patients with simultaneous HBV infection and anti-PLA2R
antibody-mediated MN until a sustained virologic remission
has been obtained by nucleos(t)ide analogue therapy. Plasma
exchange may be tried in patients with accompanying cry-
oglobulinemic vasculitis.
Children with HBV infection and MN should be managed
conservatively without immunosuppression due to a high
likelihood of spontaneous remission of the kidney disease.
Human immunodeficiency virus (HIV)–related GN. HIV-
related kidney disease is a global problem contributing
significantly to CKD rates (Figure 16). A kidney biopsy
should be performed, when feasible, to evaluate the
morphology of HIV-related kidney disease. A pathology-Figure 16 | The global distribution of CKD associated with HIV infecti
kidney disease in the global adult HIV-infected population: a systematic
2018 Ekrikpo et al. This is an open access article distributed under the t
creativecommons.org/licenses/by/4.0/). CG, Cockcroft-Gault; CKD, chroni
Collaboration; HIV, human immunodeficiency virus; MDRD, Modification
768based description of HIV-related kidney disease should be
used to help define and guide therapy. The spectrum of
kidney biopsy findings in HIV-infected patients in the mod-
ern era is shown in Figure 17.
The factors contributing to the long-term outcome of HIV
infection associated with GN are numerous and include
persistence of viral replication, response to antiviral treat-
ment, genetic predisposition to glomerular injury (e.g.,
apolipoprotein L1 [APOL1] risk alleles), coinfection with
other viruses, and development of immune complex (IC)
disease or thrombotic microangiopathy. Thus, the estimation
of prognosis in individual patients can be very difficult.
We recommend that antiretroviral therapy (ART) should be
initiated in all patients with HIV and CKD, especially biopsy-
proven HIV-associated nephropathy (HIVAN), regardless of
CD4 count, adjusted to the degree of kidney function (Grade
1C). A decision for the use of glucocorticoids as an adjunct
therapy for HIVANmust bemade on a case-by-case basis as the
risks and benefits long-term are uncertain. The presence of
CKD is not a contraindication for ART of HIV infection.
Current consensus data, based on 2 large RCTs on the time to
initiate ART, Strategic Timing of AntiRetroviral Treatment
(START) and Early Antiretroviral Treatment and/or Early
Isoniazid Prophylaxis Against Tuberculosis in HIV-infected
Adults (TEMPRANO), demonstrate benefit of early initiation
of ART at the time of diagnosis, regardless of CD4 count.
Schistosomal nephropathy. Test for appropriate endemic
coinfections (Salmonella, HBV, HCV, HIV) as targeted treat-
ment may alter the aggressiveness of an underlying GN or the
sequela of schistosomiasis. A kidney biopsy should be obtainedon. Reproduced from Ekrikpo UE, Kengne AP, Bello AK, et al. Chronic
review and meta-analysis. PLoS One. 2018;13:e0195443. Copyright ª
erms of the Creative Commons Attribution License (https://
c kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology
of Diet in Renal Disease.
Kidney International (2021) 100, 753–779
Figure 17 | The spectrum of kidney biopsy findings in patients with HIV in themodern era. Reproduced from Kidney International, volume
97, issue 5, Kudose S, Santoriello D, Bomback AS, et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era, pages
1006–1016, Copyright ª 2020, with permission from the International Society of Nephrology. A total of 26,737 native biopsies from 2010–2018
were retrospectively reviewed; 437 (1.6%) from patients with HIV-infected patients (mean age: 53 years; 66% male; 58% black; 25% white; 17%
Hispanic;<1% Asian; 80% on antiretroviral therapy [ART]; comorbidities included: 57% hypertension, 31% diabetes, 27% hepatitis C coinfection).
Conclusion from the study: ART has changed the landscape of HIV-associated kidney disease toward diverse immune complex GN, diabetic
nephropathy, and non-collapsing glomerulosclerosis, but it has not eradicated HIV-associated nephropathy. GN, glomerulonephritis; HIV, human
immunodeficiency virus; HIVAN, human immunodeficiency virus-associated nephropathy; NOS, not otherwise specified.
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ence of a viral coinfection (HCV, HBV, HIV). Patients with
schistosomal infection and GN should be treated with an
appropriate antiparasitic agent in sufficient dosage and dura-
tion to eradicate the organism. There are no indications for use
of immunosuppressive agents in schistosomal nephropathy.
Monitor patients with hepatic fibrosis from schistosomi-
asis for the development of kidney disease and evaluate pa-
tients with a history of schistosomiasis and an elevated serum
creatinine and/or hematuria for bladder cancer and/or uri-
nary obstruction.
Filariasis and glomerular disease. Patients with filarial
infection and GN should be treated with an appropriate
antiparasitic agent in sufficient dosage and duration to
eradicate the organism.
Malarial nephropathy. Malaria-related kidney disease
mostly manifests as AKI, but GN can also occur. Patients with
malarial infection and GN should be treated with an appro-
priate antiparasitic agent in sufficient dosage and duration to
eradicate the organism from blood and hepatosplenic sites.
There are no indications for use of immunosuppressive agents
in malarial nephropathy.
Chapter 8: Immunoglobulin- and complement-mediated
glomerular diseases with a membranoproliferative
glomerulonephritis pattern of injury
A membranoproliferative pattern of injury on a kidney
biopsy does not reflect a specific disease, but is a histologicKidney International (2021) 100, 753–779finding that often occurs in the setting of aberrant com-
plement activation and/or IC deposition. This led the
Work Group to suggest eliminating the term mem-
branoproliferative glomerulonephritis (MPGN) from the
new glomerular diseases guideline, in favor of a more
pathophysiologic classification of these diseases.
The diseases that can result in an MPGN pattern are
heterogeneous and require distinct therapies; they must be
properly identified beyond their histologic characteristics
(Figure 18). Fortuitously, the immunofluorescence findings
on biopsy can be used to move the work-up of these
patients in the correct direction (Figure 19). If the biopsy
is positive for immunoglobulins, with or without com-
plement components, the evaluation should be focused on
distinguishing between monoclonal deposition diseases,
autoimmune IC diseases, and infection-associated diseases.
In adults, idiopathic immune complex glomerulonephritis
(ICGN) is rare, and all other diagnostic possibilities
should be exhausted before making this diagnosis. If
immunofluorescence microscopy shows a complement-
dominant pattern, C3 or C4 glomerulopathy (C3G, C4G)
should be considered, and an appropriate evaluation of the
complement system should be undertaken. Negative
immunofluorescence should raise the possibility of several
diseases (Figure 18), but especially various types of
thrombotic microangiopathy (TMA).
Like most classification schemes, caveats apply. Com-
plement dysregulation may occur in IC glomerular769
Figure 18 | Causes of a membranoproliferative pattern of injury. CFB, complement factor B; CFH, complement factor H; CFHR5,
complement factor H–related protein 5; CFI, complement factor I; DDD, dense deposit disease; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; HUS, hemolytic-uremic syndrome; Ig, immunoglobulin; MPGN, membranoproliferative glomerulonephritis; POEMS,
polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes; SLE, systemic lupus erythematosus; TTP, thrombotic
thrombocytopenic purpura.
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cially if it is triggered by an infection. Therefore, in any case
of an apparent idiopathic ICGN, it is prudent to exclude a
complement-mediated process. Similarly, before assigning
a diagnosis of C3G, concurrent or preceding infection
should be excluded. It may be necessary to use proteolytic
digestion on paraffin-embedded biopsy tissue to detect
monoclonal immunoglobulins that may be masked during
routine immunofluorescence investigation. Monoclonal
gammopathies can initiate C3G, without glomerular
deposition of immunoglobulin, and should be considered,
especially in patients who present with C3G over the age of
50 years.
Treatment for monoclonal immunoglobulin-associated
diseases focuses on controlling the clone of B cells or770plasma cells responsible for production of the mono-
clonal immunoglobulin. Autoimmune diseases are most
often treated with immunosuppression, and infection-
associated glomerular diseases generally respond to
controlling the infection. The management of idiopathic
ICGN and C3G/C4G is less clear, and because of the
absence of any RCT data, the Work Group was able to
offer only practice points in these areas and no specific
recommendations.
In contrast to the 2012 guideline, the current approach to
idiopathic ICGN is more nuanced, as opposed to immedi-
ately committing to an immunosuppressive drug
(Figure 20). This approach tailors therapy to severity of
disease presentation and histology. Importantly, the
approach suggests restraint in treating patients aggressivelyKidney International (2021) 100, 753–779
Figure 19 | Pathophysiology of membranoproliferative lesions. DDD, dense deposit disease; GN, glomerulonephritis; HUS, hemolytic-
uremic syndrome; IC, immune complex; Ig, immunoglobulin; MPGN, membranoproliferative glomerulonephritis; TMA, thrombotic
microangiopathy.
BH Rovin et al.: Executive summary of KDIGO 2021 glomerular diseases KD IGO execu t i ve conc lu s i onswho have a chronic and significant impairment of kidney
function.
For patients with C3G inwhom amonoclonal gammopathy
has been excluded, and who have moderate-to-severe disease
(proteinuria >1 g/d and/or declining kidney function over
several months), MMF is suggested as first-line therapy.Figure 20 | Approach to idiopathic ICGN. eGFR, estimated glomerular fi
angiotensin system.
Kidney International (2021) 100, 753–779Observational data showed thatMMF decreased progression to
kidney failure compared to other immunosuppressives. After
MMF, the direction of treatment is not clear. Because C3G is a
complement-mediated disease, eculizumab has been used in a
small number of patients with variable results. While eculizu-
mab can be tried in patients who fail to respond to MMF, suchltration rate; ICGN, immune complex glomerulonephritis; RAS, renin-
771
KDIGO execu t i ve conc lu s i ons BH Rovin et al.: Executive summary of KDIGO 2021 glomerular diseasespatients should be considered for clinical trials to begin to
address this unmet need by gathering controlled study data.
Chapter 9: Antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis
ANCA-associated vasculitis (AAV) is the most common cause
for rapidly progressive kidney failure, with other important
causes being anti–glomerular basement membrane (GBM)
antibody GN and lupus nephritis (LN). The diagnostic
strategy for evaluating patients presenting with RPGN is
shown in Figure 21.
Because of the potential severity of AAV, if a patient’s
clinical presentation is compatible with a small-vessel vascu-
litis and myeloperoxidase (MPO)- or proteinase 3 (PR3)-
ANCA serology is positive, waiting for a kidney biopsy to be
done or reported to verify diagnosis should not delay starting
immunosuppressive therapy (Figure 22). The same consid-
eration is true if anti-GBM antibody GN or lupus nephritis is
suspected in a patient with RPGN. Besides confirming diag-
nosis, the kidney biopsy provides prognostic information so it
should be done when feasible. In all cases, however, infection
must be excluded with as much certainty as possible before
significant immunosuppression is given.
The initial therapy of new-onset AAV has been updated to
include induction with cyclophosphamide or rituximabFigure 21 | Diagnostic strategy in rapidly progressive glomeruloneph
antibody; GBM, glomerular basement membrane.
772combined with glucocorticoids. Recent trials, such as Plasma
Exchange and Glucocorticoids for the Treatment of ANCA-
Associated Vasculitis (PEXIVAS), have demonstrated that
glucocorticoid dosing can safely be reduced from the high-
dose regimens traditionally used in AAV. As a caveat, it was
emphasized that there are only limited data for rituximab
induction in the setting of severely impaired kidney function
(serum creatinine>4 mg/dl [>354 mmol/l]). Cyclophosphamide
remains the preferred immunosuppressive for such patients,
although the combination of cyclophosphamide plus ritux-
imab can be considered. To help in choosing whether to use
cyclophosphamide or rituximab, the Work Group provided
several suggestions (Figure 23). As noted in Figure 23, for
relapsing disease, patients should be re-induced and the
treatment of choice is rituximab, especially if patients have
already reached a cumulative dose of cyclophosphamide
over 36 g, as this may increase chances for developing a
malignancy.
One of the more controversial aspects of the initial man-
agement of AAV is the role of plasma exchange in patients
who present with severe kidney failure and/or require dialysis.
Older studies suggested a benefit, but the recently reported
PEXIVAS trial did not show that plasma exchange delayed
time to kidney failure or death in AAV patients who presented
with eGFR <50 ml/min per 1.73 m2 or alveolar hemorrhage.ritis. ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic
Kidney International (2021) 100, 753–779
Figure 22 | Biopsy strategy in suspected kidney vasculitis. ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; PR3,
proteinase 3.
Figure 23 | Factors for consideration when choosing between rituximab and cyclophosphamide for induction therapy of AAV. AAV,
ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; GN, glomerulonephritis; PR3, proteinase 3; SCr, serum creatinine.
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routinely in AAV. However, if AAV overlaps with anti-GBM
antibody GN, plasma exchange should be used.
Finally, because the treatment of AAV uses therapies that
come with considerable risk for adverse events, therapeutic
futility should be considered. The Work Group suggested that
immunosuppression be discontinued in patients who have no
extrarenal disease manifestations if after 3 months they
remain dialysis-dependent.
After induction therapy, patients with AAV require main-
tenance immunosuppression because of their high likelihoodFigure 24 | Considerations for using rituximab or azathioprine for A
antineutrophil cytoplasmic antibody; HBsAg, hepatitis B surface antigen
Kidney International (2021) 100, 753–779of relapse, especially those with PR3-ANCA disease. The
updated recommendations for AAV maintenance include
rituximab or azathioprine plus low-dose glucocorticoids,
although the Work Group preferred rituximab for mainte-
nance. Considerations for using rituximab or azathioprine are
outlined in Figure 24.
The duration of maintenance immunosuppression in AAV
is not clear. Both rituximab and azathioprine have been used
for a minimum of 18 months, and up to 4 years for azathi-
oprine. It is therefore suggested that the duration of main-
tenance therapy be at least 18 months. Withdrawal can thenAV maintenance therapy. AAV, ANCA-associated vasculitis; ANCA,
; IgG, immunoglobulin G; PR3, proteinase 3.
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Figure 25 | Factors that increase relapse risk for AAV. AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; PR3,
proteinase 3.
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(Figure 25).
Unfortunately, the commonly monitored serologies in
ANCA vasculitis are imperfect biomarkers of disease relapse.
Persistence of ANCA positivity after treatment, rising titers of
ANCA, and conversion from ANCA negativity to ANCA
positivity are only modestly predictive of future relapse;
therefore, removing maintenance therapy remains a clinical
decision, as opposed to a biomarker-driven decision for now.
Finally, if patients progress to require long-term kidney
replacement therapy, kidney transplantation should be
delayed until patients are in clinical remission for$6 months.Figure 26 | Measures to minimize the risk of complications related to
HIV, human immunodeficiency virus; LN, lupus nephritis; RAS, renin-ang
774Importantly, persistent ANCA positivity should not delay
kidney transplantation.
Chapter 10: Lupus nephritis
The management recommendations for LN are poised to
change significantly in the coming months because several
high-quality RCTs of novel therapies have recently been
successfully completed. These approaches will be incorpo-
rated into the guideline as the community understands how
best to apply the new agents in the context of existing
regimens. However, as the 2021 guideline was being estab-
lished, details of these new data were not yet available, soLN or its treatment. HBV, hepatitis B virus; HCV, hepatitis C virus;
iotensin system.
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appear not too dissimilar to the 2012 guideline. Nonethe-
less, some new management themes for LN have emerged,
and management guidelines are presented in the current
context.
It is recommended that antimalarials be given to patients
with systemic lupus erythematosus (SLE) if there are no
contraindications. Antimalarials are generally well-tolerated
and have several benefits that include reducing flare rates
(including kidney flares), decreasing organ damage, and
enhancing responsiveness to immunosuppression.
Given the systemic nature of SLE and the potential
adverse effects of therapies used to treat LN, the Work
Group noted that a holistic approach to the management
of LN be considered. Several relevant suggestions to
improve the health and well-being of LN patients are
described in Figure 26.
Considering the specific treatment of LN, there has been
an increasing realization that for proliferative forms of LN
(Class III/IV  Class V) many patients may need less intense
immunosuppression, especially with regard to glucocorticoid
exposure, than previously thought. This is reflected in the
new recommendation for the initial treatment of prolifera-
tive LN (Figure 27). Although glucocorticoids plus either
MMF or cyclophosphamide are still recommended, theFigure 27 | Comparison of recommended initial first-line treatment o
lupus nephritis; mo, month; q2, every 2.
Kidney International (2021) 100, 753–779dosing goals have been reduced compared to the prior
recommendations.
Intravenous methylprednisolone is still recommended to
initiate therapy, but the cumulative dose has been reduced,
followed by a lower starting dose of oral prednisone that is
tapered fairly rapidly. MMF and cyclophosphamide remain
the 2 recommended first-line immunosuppressive drugs.
Initial MMF dosing has not changed, but low-dose intrave-
nous cyclophosphamide (the Euro-Lupus regimen, Figure 27
lower panel) has replaced high-dose cyclophosphamide (the
National Institutes of Health regimen) and oral cyclophos-
phamide as the method of choice to give an alkylating agent.
In contrast, for patients with very severe proliferative LN,
either histologically (abundant crescents, glomerular capillary
necrosis) and/or clinically (rapid deterioration of kidney
function), treating physicians may elect to use more tradi-
tional intense immunosuppression up-front. This recom-
mendation and associated practice points provide sufficient
latitude to individualize initial therapy.
The combination of a glucocorticoid, MMF, and a CNI,
the so-called “multitarget” regimen, shows good efficacy
compared to cyclophosphamide. Because the multitarget
regimen had not been studied in diverse lupus populations, it
was not recommended as first-line treatment, but suggested
as an alternative for MMF and cyclophosphamide. However,f proliferative LN in the 2012 versus KDIGO 2021 guideline. LN,
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approved the addition of the novel CNI, voclosporin, to
prednisone and MMF for the treatment of adults with active
LN (Classes III, IV, V, and mixed) based on the results of a
positive multicenter, multinational phase 3 trial. Voclosporin
has not been studied with cyclophosphamide. After these data
have been systematically reviewed, multitarget therapy will be
reassessed for recommendation. Of likely importance to pa-
tients, the voclosporin regimen is significantly glucocorticoid-
sparing, and will hopefully reduce the glucocorticoid adverse
events often seen during LN treatment.
Biologics such as rituximab, which targets a B-cell surface
marker, or belimumab, a monoclonal antibody to the B-cell
growth and survival factor, B-cell activating factor (BAFF), are
not included in the recommendation of first-line treatment.
Biologics are, however, discussed in a practice point, noting
that there are positive data from recent clinical trials
demonstrating that biologics are effective in LN, and have
favorable safety profiles.
The history of biologics for the treatment of LN is storied.
Although the initial trials of rituximab and abatacept held
considerable promise for modifying LN treatment, neither
agent proved better when added to standard of care than
placebo. Despite these negative trials, rituximab enjoys
considerable off-label use, and in uncontrolled but real-world
patient settings, is frequently reported to be effective. At the
same time, clinical trialists, having learned lessons from failed
trials, designed new trials that have been successful.
Regulatory approval from the US Food and Drug
Administration of a biologic for LN came in December 2020
after the Efficacy and Safety of Belimumab in Patients with
Active Lupus Nephritis (BLISS-LN) trial demonstrated that
belimumab was more effective than placebo in achieving aFigure 28 | Maintenance therapy for Class III and Class IV LN. The targ
KDIGO Work Group acknowledges that targets for glomerular diseases a
and avoid CNI toxicity. At present, the most reasonable dosing of a CNI m
on proteinuria, balancing dose escalation against serum creatinine and re
increases over 30% of baseline. If the serum creatinine level does not fall
inhibitor; LN, lupus nephritis.
776primary efficacy renal response (PERR) at 2 years (43% vs.
32%; odds ratio 1.6; P ¼ 0.03) when added to background
therapy of glucocorticoids plus either MMF or low-dose
cyclophosphamide. The PERR is a novel endpoint for LN
trials and was defined as a PCR <0.7, an eGFR that was
no worse than 20% below baseline or at least 60 ml/min per
1.73 m2, and no treatment failure. The optimal use of beli-
mumab in LN will become clear as its use increases, and the
BLISS-LN data will be incorporated into the evidence review.
After completion of initial therapy for proliferative LN, a
MPAA is recommended for ongoing immunosuppression
(Figure 28). As shown, alternative long-term treatments are
available and may be used in cases of intolerance to a specific
therapy or if other special circumstances arise. For example,
MPAA should not be used during pregnancy, but azathioprine
and CNIs can be given.
One of the critical and as yet unsettled questions in the
management of LN is the overall duration of immunosup-
pression. The pros and cons of prolonged immunosuppres-
sion hinge on balancing the risk of lupus relapse with the risk
of adverse events secondary to immunosuppressive drugs.
There are few high-quality data to support a specific duration
of immunosuppression, although it is suggested that for pa-
tients who have achieved a complete kidney response and
have no ongoing extrarenal SLE manifestations, the total
duration of immunosuppression (initial plus maintenance)
should not be <36 months. In the overall context of with-
drawal of immunosuppression, it is suggested that glucocor-
ticoid discontinuation may be considered after patients have
maintained a complete clinical response for about a year, and
have no extrarenal disease requiring glucocorticoids. These
suggestions imply that patients who do not achieve a com-
plete kidney remission, but only a partial remission, wouldet ranges for CNIs have been based on the transplant literature. The
re not known. Most clinicians check these levels to verify adherence
ay be to titrate in the individual patient to obtain the desired effect
ducing the dose if serum creatinine increases but does not plateau or
after dose reduction, the CNI should be discontinued. CNI, calcineurin
Kidney International (2021) 100, 753–779
Figure 29 | Management of patients with pure Class V LN. LN, lupus nephritis.
BH Rovin et al.: Executive summary of KDIGO 2021 glomerular diseases KD IGO execu t i ve conc lu s i onsneed to be kept on immunosuppression indefinitely. How-
ever, repeat biopsy studies have shown that while persistent
histologic activity is a risk factor for LN relapse, many pa-
tients who have achieved only a partial clinical remission have
no remaining activity on kidney biopsy. Thus, a more focused
use of repeat kidney biopsies may help in managing the
duration of immunosuppression.
Of the histologic types of LN, the membranous form
(Class V) has received the least attention in terms of specific
clinical trials. However, several of the newer trials evaluating
novel treatments included patients with pure Class V LN.
Subgroup analyses will help in understanding if these new
agents have a role in Class V management. Until then, theFigure 30 | Commonly used definitions of response to therapy in LN
proteinuria <0.5 g/1.73 m2/d or <300 mg/m2/d based on a 24-hour uri
Kidney International (2021) 100, 753–779suggested approach to pure Class V LN (Figure 29) has not
materially changed since the last glomerular disease guideline.
One of the issues facing the evaluation of novel LN therapies
is defining a meaningful response to treatment. The common
definitions (Figure 30) are based on clinical thresholds and
timelines that may be optimistic and used more to keep trial
costs under control than for pathophysiologic reasons. Protocol
repeat biopsy studies have shown that clinical responses and
histologic improvement of the kidneys may be discordant.
The biomarkers used clinically for the evaluation of LN
activity, such as complement levels and anti–double-stranded
DNA titers, also have limitations. Therefore, the Work Group
suggested that if patients are improving, allowing 18–24. *For children <18 years old, complete response is defined as
ne specimen. LN, lupus nephritis; PCR, protein-creatinine ratio.
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clinic and outside of the clinical trial setting. Importantly,
many of the new trial designs are incorporating a longer
timeline to assess clinical response.
Chapter 11: Anti-GBM antibody GN
The recommended therapy for anti-GBM antibody GN had
not changed from the 2012 Glomerulonephritis guideline.
Patients should be treated with glucocorticoids, cyclophos-
phamide, and plasmapheresis (Grade 1C). However, in the
absence of pulmonary hemorrhage, if a patient requires dialysis
at presentation and their kidney biopsy shows 100% crescents
or more than 50% global glomerulosclerosis, the risk of this
intense immunosuppressive protocol is difficult to justify given
the very poor prognosis for sufficient recovery of kidney
function to discontinue dialysis. Because anti-GBM disease
may progress rapidly, if there is a high degree of suspicion for
the diagnosis, treatment should not be delayed by the logistics
of performing or interpreting a kidney biopsy. The biopsy can
be done after treatment has been initiated. Importantly, for
patients who do respond to therapy and recover, maintenance
therapy with an immunosuppressive is not required as anti-
GBM disease only rarely relapses. However, if a patient is
positive for both anti-GBM antibodies and ANCA (up to 30%
of patients), they should be given maintenance immunosup-
pression, as would be done for patients with AAV.
Other therapies have been tried for anti-GBM disease, but
these have been mainly in the context of case reports or small,
uncontrolled series. For example, rituximab has been suc-
cessfully used for patients who have incompletely responded
to the recommended approach. There have also been reports
successfully substituting MMF for cyclophosphamide in the
treatment of anti-GBM disease. Given the rarity of anti-GBM
GN and its severity, it is understandable why progress toward
new treatments has been limited.
Conclusion
The KDIGO 2021 Guideline for the Management of
Glomerular Diseases is an extensive evaluation of literature
and data supporting the management of patients with
glomerular diseases. Although there has been significant
progress made in treatment since the first guideline in 2012, it
is clear that practice points greatly outnumber recommen-
dations in the guideline. It is the hope of all those involved in
the generation of this guideline that the document will serve
as impetus to move clinical research in glomerular diseases
forward so the unanswered questions raised here can be
addressed and new evidence be made available to incorporate
into the next iteration of recommendations. This guideline is
intended to be a “living document” that will be updated as the
nephrology community generates new high-quality data.
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